Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: The ANRS COPANA cohort

Antiviral Therapy

Volumn 17, Issue 1, 2012, Pages 91-100

  Boufassa, Faroudy ^a,b,c   Goujard, Cécile ^a,b,c   Viard, Jean Paul ^d   Carlier, Robert ^e   Lefebvre, Bénédicte ^f   Yeni, Patrick ^g   Bouchaud, Olivier ^h   Capeau, Jacqueline ^i,j,k   Meyer, Laurence ^a,b,c   Vigouroux, Corinne ^i,j,k  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICÊTRE HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g BICHAT HOSPITAL   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^j SORBONNE UNIVERSITÉ   (France)

^k HÔPITAL TENON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADIPOSE TISSUE; ADULT; AGE; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; SEX; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

ADIPOKINES; ADULT; AFRICA SOUTH OF THE SAHARA; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; BODY MASS INDEX; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CYTOKINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FRANCE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HUMANS; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS; MALE; RISK FACTORS; RNA, VIRAL;

EID: 84856158153     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1916     Document Type: Article

References (39)

1. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The 'Mortalité 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
2. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9:72-81. (Pubitemid 351232645)
3. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184. (Pubitemid 40720744)
4. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
5. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45:111-119. (Pubitemid 46984626)
6. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31:1224-1229.
7. Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008; 46:1101-1110.
8. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50:499-505.
9. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
10. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23:929-939.
11. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841-1849.
12. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241. (Pubitemid 351160160)
13. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-1067.
14. Gianotti N, Visco F, Galli L, et al. Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. HIV Med 2011; 12:109-117.
15. Rotger M, Gsponer T, Martinez R, et al. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clin Infect Dis 2010; 51:1090-1098.
16. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010; 33:2244-2249.
17. Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007; 12:149-162. (Pubitemid 46569900)
18. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005; 6:114-121. (Pubitemid 40425975)
19. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect 2005; 50:331-337. (Pubitemid 40533370)
20. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
21. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160-3167.
22. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.
23. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375-1383. (Pubitemid 41800673)
24. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52:812-817. (Pubitemid 36323590)
25. Dixon AK. Abdominal fat assessed by computed tomography: sex difference in distribution. Clin Radiol 1983; 34:189-191. (Pubitemid 13157497)
26. Seidell JC, Oosterlee A, Thijssen MA, et al. Assessment of intra-abdominal and subcutaneous abdominal fat: relation between anthropometry and computed tomography. Am J Clin Nutr 1987; 45:7-13. (Pubitemid 17030258)
27. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17:1503-1511. (Pubitemid 36900551)
28. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14:741-751.
29. Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991; 40:651-656.
30. Howard AA, Hoover DR, Anastos K, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2010; 54:152-159.
31. Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-Infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr 2007; 45:66-71. (Pubitemid 46684444)
32. + T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435-447.
33. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982. (Pubitemid 37430100)
34. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327:329-337.
35. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45:1169-1196. (Pubitemid 38802622)
36. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
37. Hellerstein MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 76:559-565. (Pubitemid 23086466)
38. Woods MN, Wanke CA, Ling PR, et al. Metabolic syndrome and serum fatty acid patterns in serum phospholipids in hypertriglyceridemic persons with human immunodeficiency virus. Am J Clin Nutr 2009; 89:1180-1187.
39. Szep Z, Guaraldi G, Shah SS, et al. Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS 2011; 25:525-529.